Tetraphase's Broad-Spectrum Antibiotic Makes A Good Showing At ICAAC
This article was originally published in Pharmaceutical Approvals Monthly
BOSTON - Start-up Tetraphase Pharmaceuticals created buzz at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston Sept. 12-15 with its platform of synthetic tetracyclines
You may also be interested in...
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011